Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11184060 | 0.87 | KDM4E (0.49) | MCL1MAPTTSHRNPY1RNPY2R | |
| SCHEMBL6564428 | 0.83 | KDM4E (0.56) | MCL1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL2205828 | 0.81 | MAPT (0.50) | MAPTKMT2ASMN1; SMN2POLBCA12 | |
| SCHEMBL1145316 | 0.80 | SLC6A4 (0.54) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL29768449 | 0.80 | SLC6A4 (0.54) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL11087092 | 0.79 | KMT2A (0.50) | MCL1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL882328 | 0.79 | MCL1 (0.50) | MCL1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL1000564 | 0.79 | TDP1 (0.44) | MAPTTSHRKMT2AKDM4ECA12 | |
| SCHEMBL3757525 | 0.79 | MCL1 (0.50) | MCL1KMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL19785375 | 0.78 | HSP90AA1 (0.56) | MAPTTSHRKMT2AKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57193435-A | — | — | None | — | — | JP | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| WO-2024015055-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-0274867-A2 | Pharmaceutically active compounds | SCHERING CORPORATION (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
| US-4448971-A | Hypoglycemic 5-phenyl-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1984-05-15 | — | — | US | disclosed |
| EP-0045423-B1 | PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| US-4407811-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4399296-A | TRIMETHYLSILYL CYANOHYDRIN INTERMEDIATES | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4367234-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1983-01-04 | — | — | US | disclosed |
| JP-S57193435-A | PRODUCTION OF DIPHENYLAMINE | NIPPON KAYAKU CO LTD | 1982-11-27 | — | — | JP | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | MCL1 4793/4885MAPT 1152/4885TSHR 2377/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | MCL1 4793/4885MAPT 1152/4885TSHR 2377/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | MCL1 2451/4885MAPT 4803/4885TSHR 437/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | MCL1 4501/4885MAPT 4737/4885TSHR 204/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | MCL1 552/4885MAPT 3674/4885TSHR 1696/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | MCL1 1805/4885MAPT 4477/4885TSHR 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.